Open Access
Issue |
Med Sci (Paris)
Volume 39, Number 4, Avril 2023
|
|
---|---|---|
Page(s) | 335 - 343 | |
Section | M/S Revues | |
DOI | https://doi.org/10.1051/medsci/2023008 | |
Published online | 24 April 2023 |
- Jager KJ, Kovesdy C, Langham R, et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int 2019 ; 96 : 1048–1050. [CrossRef] [PubMed] [Google Scholar]
- Fried LF, Folkerts K, Smeta B, et al. Targeted literature review of the burden of illness in patients with chronic kidney disease and type 2 diabetes. Am J Manag Care 2021; 27 : S168–77. [CrossRef] [PubMed] [Google Scholar]
- Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2020; 98 : S1–115. [CrossRef] [PubMed] [Google Scholar]
- Chang TI, Li S, Chen S-C, et al. Risk factors for ESRD in individuals with preserved estimated GFR with and without albuminuria: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2013 ; 61 : S4–11. [CrossRef] [PubMed] [Google Scholar]
- Jankowski J, Floege J, Fliser D, et al. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation 2021; 143 : 1157–72. [CrossRef] [PubMed] [Google Scholar]
- Fang M, Wang D, Coresh J, et al. Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018. N Engl J Med 2021; 384 : 2219–28. [CrossRef] [PubMed] [Google Scholar]
- Barrera-Chimal J, Bonnard B, Jaisser F. Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases. Annu Rev Physiol 2022; 84 : 585–610. [CrossRef] [PubMed] [Google Scholar]
- Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 2021; 42 : 152–61. [CrossRef] [PubMed] [Google Scholar]
- Barrera-Chimal J, Lima-Posada I, Bakris GL, et al. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects. Nat Rev Nephrol 2022; 18 : 56–70. [CrossRef] [PubMed] [Google Scholar]
- Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Primer 2015 ; 1 : 15018. [CrossRef] [Google Scholar]
- DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol 2021; 17 : 319–34. [CrossRef] [PubMed] [Google Scholar]
- Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 2010 ; 6 : 319–330. [CrossRef] [PubMed] [Google Scholar]
- Barrera-Chimal J, Jaisser F. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets. Diabetes Obes Metab 2020; 22 Suppl 1 : 16–31. [CrossRef] [PubMed] [Google Scholar]
- Jaisser F, Farman N. Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology. Pharmacol Rev 2016 ; 68 : 49–75. [CrossRef] [PubMed] [Google Scholar]
- Kintscher U, Bakris GL, Kolkhof P. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol 2022; 179 : 3220–34. [CrossRef] [PubMed] [Google Scholar]
- Bauersachs J, Lother A. Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms. Kidney Int Suppl 2022; 12 : 19–26. [CrossRef] [Google Scholar]
- Grune J, Beyhoff N, Smeir E, et al. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic Activity. Hypertens Dallas Tex 1979 ; 2018 : 71 : 599–608. [Google Scholar]
- Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007 ; 3 : 486–492. [CrossRef] [PubMed] [Google Scholar]
- Holman RR, Paul SK, Bethel MA, et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008 ; 359 : 1565–1576. [CrossRef] [PubMed] [Google Scholar]
- Kakar F, Weiss NS, Strite SA. Non-contraceptive estrogen use and the risk of gallstone disease in women. Am J Public Health 1988 ; 78 : 564–566. [CrossRef] [PubMed] [Google Scholar]
- Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021; 9 : 653–62. [CrossRef] [PubMed] [Google Scholar]
- Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 ; 341 : 709–717. [CrossRef] [PubMed] [Google Scholar]
- Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003 ; 348 : 1309–1321. [CrossRef] [PubMed] [Google Scholar]
- Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94–8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013 ; 34 : 2453–2463. [CrossRef] [PubMed] [Google Scholar]
- Bakris GL, Agarwal R, Chan JC, et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA 2015 ; 314 : 884–894. [CrossRef] [PubMed] [Google Scholar]
- Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 2016 ; 37 : 2105–2114. [CrossRef] [PubMed] [Google Scholar]
- Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020; 383 : 2219–29. [CrossRef] [PubMed] [Google Scholar]
- Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021; 385 : 2252–63. [CrossRef] [PubMed] [Google Scholar]
- Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022; 43 : 474–84. [CrossRef] [PubMed] [Google Scholar]
- Agarwal R, Anker SD, Filippatos G, et al. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrol Dial Transplant 2022; 37 : 1261–9. [CrossRef] [PubMed] [Google Scholar]
- Agarwal R, Joseph A, Anker SD, et al. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol 2022; 33 : 225–37. [CrossRef] [PubMed] [Google Scholar]
- Thompson S, James M, Wiebe N, et al. Cause of Death in Patients with Reduced Kidney Function. J Am Soc Nephrol 2015 ; 26 : 2504–2511. [CrossRef] [PubMed] [Google Scholar]
- Tuttle KR, Alicic RZ, Duru OK, et al. Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children: An Analysis of the CURE-CKD Registry. JAMA Netw Open 2019 ; 2 : e1918169. [CrossRef] [PubMed] [Google Scholar]
- McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiol 2021; 6 : 148–58. [CrossRef] [PubMed] [Google Scholar]
- Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 2015 ; 372 : 222–231. [CrossRef] [PubMed] [Google Scholar]
- Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015 ; 372 : 211–221. [CrossRef] [PubMed] [Google Scholar]
- Barrera-Chimal J, Gerarduzzi C, Rossignol P, et al. The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease. Clin Sci 2022; 136 : 1005–17. [CrossRef] [PubMed] [Google Scholar]
- Neuen BL, Oshima M, Agarwal R, et al. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation 2022; 145 : 1460–70. [CrossRef] [PubMed] [Google Scholar]
- van der Beek AB, Boer RA, Heerspink HJL. Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat Rev Nephrol 2022; 18 : 294–306. [CrossRef] [PubMed] [Google Scholar]
- Provenzano M, Puchades MJ, Garofalo C, et al. Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial. J Am Soc Nephrol 2022; 33 : 1569–80. [CrossRef] [PubMed] [Google Scholar]
- Green JB, Mottl AK, Bakris G, et al. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using an UACR Endpoint study (CONFIDENCE). Nephrol Dial Transplant 2022; gfac198. [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.